Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Hodgkin Disease 5Leukemia, Biphenotypic, Acute 4Hematologic Neoplasms 4Leukemia, Myelomonocytic, Chronic 3Anemia, Refractory, with Excess of Blasts 3Sarcoma 2Rhabdomyosarcoma 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioblastoma 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Ewing 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1

Interventions

Temozolomide 6Cyclophosphamide 5cabozantinib 4Vincristine 4fludarabine 3Radiotherapy 3Irinotecan 3liposomal doxorubicin 2irinotecan sucrosofate 2Zoledronic Acid 2Topotecan 2Specimen Handling 2PM 01183 2Ifosfamide 2Etoposide 2Eflornithine 2Drug Therapy 2Doxorubicin 2trilaciclib 1trifluridine tipiracil drug combination 1talazoparib 1silmitasertib 1romiplostim 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1naxitamab 1fluzoparib 1fludarabine phosphate 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Ewing × Filgrastim × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡